Int J Med Sci 2020; 17(16):2511-2530. doi:10.7150/ijms.46378 This issue Cite

Research Paper

Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology

Xiao Chen1,3, Yun-Hong Yin2, Meng-Yu Zhang1, Jian-Yu Liu1, Rui Li1, Yi-Qing Qu2✉

1. Department of Pulmonary and Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
2. Department of Pulmonary and Critical Care Medicine, Qilu Hospital, Shandong University, Jinan, China.
3. Department of Respiratory Medicine, Tai'an City Central Hospital, Tai'an, China.

Citation:
Chen X, Yin YH, Zhang MY, Liu JY, Li R, Qu YQ. Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology. Int J Med Sci 2020; 17(16):2511-2530. doi:10.7150/ijms.46378. https://www.medsci.org/v17p2511.htm
Other styles

File import instruction

Abstract

ShuFeng JieDu capsule (SFJDC), a traditional Chinese medicine, has been recommended for the treatment of COVID-19 infections. However, the pharmacological mechanism of SFJDC still remains vague to date. The active ingredients and their target genes of SFJDC were collected from TCMSP. COVID-19 is a type of Novel Coronavirus Pneumonia (NCP). NCP-related target genes were collected from GeneCards database. The ingredients-targets network of SFJDC and PPI networks were constructed. The candidate genes were screened by Venn diagram package for enrichment analysis. The gene-pathway network was structured to obtain key target genes. In total, 124 active ingredients, 120 target genes of SFJDC and 251 NCP-related target genes were collected. The functional annotations cluster 1 of 23 candidate genes (CGs) were related to lung and Virus infection. RELA, MAPK1, MAPK14, CASP3, CASP8 and IL6 were the key target genes. The results suggested that SFJDC cloud be treated COVID-19 by multi-compounds and multi-pathways, and this study showed that the mechanism of traditional Chinese medicine (TCM) in the treatment of disease from the overall perspective.

Keywords: ShuFeng JieDu capsule, Novel Coronavirus Pneumonia, network pharmacology, mechanism, pathway, candidate genes


Citation styles

APA
Chen, X., Yin, Y.H., Zhang, M.Y., Liu, J.Y., Li, R., Qu, Y.Q. (2020). Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology. International Journal of Medical Sciences, 17(16), 2511-2530. https://doi.org/10.7150/ijms.46378.

ACS
Chen, X.; Yin, Y.H.; Zhang, M.Y.; Liu, J.Y.; Li, R.; Qu, Y.Q. Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology. Int. J. Med. Sci. 2020, 17 (16), 2511-2530. DOI: 10.7150/ijms.46378.

NLM
Chen X, Yin YH, Zhang MY, Liu JY, Li R, Qu YQ. Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology. Int J Med Sci 2020; 17(16):2511-2530. doi:10.7150/ijms.46378. https://www.medsci.org/v17p2511.htm

CSE
Chen X, Yin YH, Zhang MY, Liu JY, Li R, Qu YQ. 2020. Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology. Int J Med Sci. 17(16):2511-2530.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image